EUCTR2019-001730-34-GB进行中（未招募）1 期
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The following inclusion criteria must be met for all transplant recipients (i.e., recipients to be administered TX200-TR101 and control recipients):
- •Inclusion Criteria (All Transplant Recipients)
- •1. Willing and able to provide written informed consent (IC) in accordance with local regulations and governing Independent Ethics Committee (IEC)/Institutional Review Board (IRB) requirements prior to any procedure or evaluation performed specifically for the sole purpose of the study.
- •2. Male or female aged between 18 and 70 (inclusive) years.
- •3. Have diagnosis of ESRD and currently waiting for a new kidney from an identified live donor.
- •4. Subjects who will be single organ recipients (kidney).
- •5. Women who are of childbearing potential must have a negative serum pregnancy test at screening and before transplantation.
- •6. Able and willing to use a highly effective method of contraception from the signing of the informed consent through the last study visit, for male and female subjects with reproductive potential.
- •Additional Inclusion Criteria (Transplant Recipients to be Administered TX200-TR101 Only)
- •The following additional criteria must be met for transplant recipients to be administered TX200- TR101:
- •1. HLA-A*02 negative typing (the kidney graft needs to be HLA A*02 positive).
- •2. HLA-A*69 negative typing.
- •3. Adequate venous access for leukapheresis, and no other contraindications for leukapheresis.
- •Additional Inclusion Criteria (Transplant Donors for Transplant Recipients to be Administered TX200- TR101 Only)
- •The following additional inclusion criterion must be met for transplant donors for transplant recipients to be administered TX200-TR101:
- •1. HLA-A*02 positive typing.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •Exclusion Criteria (All Transplant Recipients)
- •1.HLA identical to the prospective organ donor.
- •2.Subjects with prior organ transplant.
- •3.Positive flow cytometric crossmatch using donor lymphocytes and recipient serum.
- •4.Subjects with panel-reactive antibody (PRA) >20% within 6 months prior to enrolment.
- •5. Subjects with current or recent (within 6 months) donor-specific antibodies.
- •6. Subjects with underlying renal disease with a high risk of disease reoccurrence in the transplanted kidney including primary focal segmental glomerulosclerosis, types I or II membranoproliferative glomerulonephritis, C3 glomerulopathy, or haemolytic-uraemic syndrome (HUS), including atypical HUS.
- •7. Concomitant clinically active local or systemic infection.
- •8. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases (i.e., cardiovascular, pulmonary, haematologic, gastrointestinal, hepatic, neurological, malignancy or infectious diseases) or laboratory abnormality (except ESRD) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk.
研究者
相似试验
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsEUCTR2019-001730-34-DESangamo Therapeutics France SAS60
招募中
2 期
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients.Allograft rejection1002766510029149Renal transplant rejectionNL-OMON56213Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsPrevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865EUCTR2019-001730-34-BESangamo Therapeutics France SAS60
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsEUCTR2019-001730-34-NLSangamo Therapeutics France SAS42
进行中（未招募）
1 期
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients (STEADFAST)CTIS2024-512579-11-00Sangamo Therapeutics France60